Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.
S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a multidisciplinary tumor board (Abstract S6-07).
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
